RxDoctor Payments Data

Richard Markiewicz, MD

Interventional Cardiology · North Platte, NENPI 1780725580

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 86.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $17,949 and has fallen 99.9% since, to $14 in 2025.

$32,650in general payments, 2019–2025

Across 127 payments — averaging $257.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$28K
  • Medtronic$2K
  • Boston Scientific$1K
  • Terumo Medical Corporation$522
  • Philips North America LLC$238
  • Siemens Medical Solutions USA, Inc.$200
  • plus $722 from 14 others

What the payments were for

  • Consulting fees$16,00049%
  • Speaking & faculty fees$9,25028%
  • Travel & lodging$3,75712%
  • Food & beverage$3,64311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,650 in reported general payments places this provider in the 80th percentile of 50 interventional cardiology providers in Nebraska.

See all interventional cardiology providers in Nebraska

Medicare billing

Part B allowed, 2024
$212,094
Medicare patients
1,074
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$29,865
Repatha SureclickEvolocumab30$20,537
XareltoRivaroxaban16$12,954
ClopidogrelClopidogrel Bisulfate377$3,157
Ranolazine ErRanolazine50$2,096
Atorvastatin Calcium194$1,359
Carvedilol150$1,268
Pantoprazole Sodium89$1,038
Isosorbide Mononitrate ErIsosorbide Mononitrate74$835
Metoprolol Succinate80$808
Bumetanide15$463
Rosuvastatin Calcium42$442
Metoprolol Tartrate67$388
Losartan Potassium54$321
Amlodipine Besylate64$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$29,86533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 interventional cardiology providers in Nebraska.

Other interventional cardiology in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →